Generic Pricing Pressure Could Become "Significant" During 2006
This article was originally published in The Pink Sheet Daily
With additional ANDAs for already-generic products moving towards approval, the segment will see notable uptick in competition, ABN AMRO's Erdei says.
You may also be interested in...
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.